drugset

drugset / Trial / NCT06710158

Study of SC-102 in Patients With Advanced Solid Tumors

NCT06710158 ↗

Phase 1 Recruiting 120 enrolled Tianjin ConjuStar Biologics Co., Ltd.

Non-randomizedSequentialOpen-labelTreatment

Summary

This study will evaluate the safety, PK profile, and anti-cancer efficacy of SC-102 in subjects with advanced solid tumors

Timeline

Start: 2024-12-05
Primary completion: 2026-12
Completion: 2027-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SC-102	Peptide	—	—

Indications